Planta Med 2008; 74 - PA174
DOI: 10.1055/s-0028-1084172

Anti-cancer effects of malvidin-3,5-diglucoside from Alcea longipedicellata, on gastric cancer cell line (AGS)

YY Kamrani 1, B Esmaeelian 2, M Jabbari 3, B Tabaraei 4, A Yazdanyar 5, SN Ebrahimi 1
  • 1Department of Phytochemistry, Medicinal Plants and Drugs Research Institute, Shahid Beheshti University, Evin, Tehran, Iran. P.O. Box:19835–389
  • 2Department of Pharmacology, Faculty of Veterinary Medicine, University of Tehran, Iran
  • 3Department of Nephrology, Iran University of Medical Sciences, Tehran, Iran
  • 4Department of Bacterial Vaccine and Antigen Production, Pasteur Institute of Iran, Tehran, Iran
  • 5Department of Biochemistry, School of Medicine, Tehran University of Medical Sciences and Health Services, Tehran, Iran

Gastric and gastroesophageal adenocarcinomas are important health problems. Extensive studies have indicated that anthocyanins like anthocyanidins, delphinidin and malvidin have strong antioxidant and anti-cancer activities [1]. The aim of present study is evaluation of the antiproliferative and apoptotic effects of malvidin-3,5-diglucoside(malvin). Malvin showed direct cytotoxicity on AGS-C131 in a concentration-dependent manner, with IC50 values of 140.6µM, respectively. Apoptotic AGS cells were also demonstrated by TUNEL labeling [2]. Malvin treatment for 24h resulted in an appreciable arrest of cells in the G0-G1 phase of the cell cycle (81.6% vs. 65.2% of control). Moreover the G2-M cell population increased after 24h incubation with control medium following malvin treatment, indicating that the G0-G1 arrest by malvin was reversible. The combination effect of malvin with cis-platin(cDDP) was evaluated by MTT assay in AGS. Malvin followed by cDDP showed weak synergy in AGS cell line, while cDDP followed by malvin showed an additive antitumor effect in cell line. Simultaneous dosage with the two agents showed an antagonistic antitumor effect in both lines. Taken together, our results suggest that malvidin-3,5-diglucoside may represent one component of a new treatment protocol for the suppression of gastric cancer, with less side-effects over existing therapy.

References: 1. Kobori, M. (2003) JARQ 37: 1275–78.

2. Stavric, B. (1994) Food Chem. Toxicol. 32: 79–90